Exploring Tumor Biology in Ovarian Cancer with Advanced Imaging Techniques

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to enhance the understanding of tumor heterogeneity in high-grade serous ovarian cancer by integrating in vivo MRI imaging with ex vivo histological and molecular assessments. Patients will undergo imaging before surgery, and tissue and blood samples will be collected during the surgical procedure for further analysis. The goal is to develop non-invasive methods for characterizing tumors, which could lead to more personalized treatment approaches.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient aged \>18
* Pathologically proven HGSOC at an advanced stage (FIGO IIIB or IIIC) which can benefit from surgery with or without prior neoadjuvant treatment
* Willingness and ability to comply with planned visits, treatment plan, laboratory tests and other study procedures,
* Patient who has given informed, written and express consent,
* Patient affiliated with a French health insurance scheme.

Exclusion Criteria:

* Early-stage disease (FIGO \<IIIB) or presence of extraperitoneal metastases,
* Patient who will not have surgery
* Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons,
* Patient under guardianship, curatorship or safeguarding of justice,
* Pregnant and/or nursing patient,
* Patient with a history of other cancers within 5 years/10 years prior to inclusion

Where it's running

• NOUGARET Stephanie
  Montpellier, France Recruiting

Study contacts

• Study coordinator: MOUSSION Aurore
• Email: aurore.moussion@icm.unicancer.fr
• Phone: 0467613102

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• FRα expression in high-grade serous ovarian cancer (FRα positive)

  A retrospective study in Greece will test how often Folate Receptor Alpha is present in tumor samples from adults diagnosed with high-grade serous ovarian cancer.

  Recruiting Hellenic Cooperative Oncology Group · Athens · NCT07889843

• Routine shallow-coverage Whole Genome Sequencing of Cervical Smears to See if Ovarian Cancer is Found Earlier

  Researchers test whether analyzing DNA from cervical smears with shallow whole-genome sequencing can help detect high-grade serous ovarian cancer early in patients undergoing treatment for this cancer.

  Recruiting Institut Claudius Regaud · Toulouse · NCT07821879

• IDE034 for adults with advanced solid tumors that express B7-H3 and PTK7

  This trial will test IDE034 to see if it is safe and works in adults with advanced or metastatic solid tumors that express B7-H3 and PTK7.

  Recruiting at 26 sites Phase 1 IDEAYA Biosciences · Duarte, California and 25 other locations · NCT07503808

• Idetrexed plus olaparib for high-grade serous ovarian cancer

  This trial tests whether combining idetrexed and olaparib helps people with high-grade serous ovarian cancer that is resistant to standard treatments.

  Recruiting Phase 1 Institute of Cancer Research, United Kingdom · Cambridge, Cambridgeshire and 2 other locations · NCT06976892

• Investigating the Role of RPL8 Protein in Ovarian Cancer

  This study is trying to see if the RPL8 protein in ovarian cancer tumors can help doctors understand the disease better and make more informed treatment choices for patients.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, BO · NCT06777082

• Testing Rinatabart Sesutecan for advanced solid tumors

  This study is testing a new drug called Rinatabart Sesutecan to see if it can safely help people with advanced solid tumors, like certain types of ovarian and endometrial cancers.

  Recruiting at 67 sites Phase 1/2 Genmab · Phoenix, Arizona and 66 other locations · NCT05579366

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.